VOLUME 9 (2018)
View Archive »
About The Cover
The cover for issue 87 of Oncotarget features Figure 1, "The survival rate of genetically engineered mice with pancreatic ductal adenocarcinoma treated with a weekly injection of nano-albumin bound paclitaxel (NAB-paclitaxel) alone (orange line, n = 4), NAB-paclitaxel 3 hours after CYT-6091 treatment (green line, n = 4), and vehicle control (blue line, n = 3)," by Libutti, et al.
|
|
Table of Contents
News
|
| MiRNAs prognostic for basal and BRCA1 breast cancer |
|
https://doi.org/10.18632/oncotarget.26297
|
| 35717-35718 |
Editorial
|
| A triple drug combination as a novel antiglioma therapy |
|
https://doi.org/10.18632/oncotarget.26279
|
| 35719-35720 |
|
| Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD |
|
https://doi.org/10.18632/oncotarget.26291
|
| 35721-35722 |
Research Perspectives
|
| Targeting the invincible barrier for drug delivery in solid cancers: interstitial fluid pressure |
|
https://doi.org/10.18632/oncotarget.26267
|
| 35723-35725 |
Research Papers
|
| Loss of miR198 and 206 during primary tumor progression enables metastatic dissemination in human osteosarcoma |
|
https://doi.org/10.18632/oncotarget.26284
|
| 35726-35741 |
|
| Histologic subtyping in pathologic stage IIIA lung adenocarcinoma provides riskbased stratification for surveillance |
|
https://doi.org/10.18632/oncotarget.26285
|
| 35742-35751 |
|
| Immunomodulatory effect of statins on Regulatory T Lymphocytes in human colorectal cancer is determined by the stage of disease |
|
https://doi.org/10.18632/oncotarget.26293
|
| 35752-35761 |
|
| Cytotoxicity of nimbolide towards multidrugresistant tumor cells and hypersensitivity via cellular metabolic modulation |
|
https://doi.org/10.18632/oncotarget.26299
|
| 35762-35779 |
Clinical Research Papers
|
| Bloodstream infection due to Escherichia coli in liver cirrhosis patients: clinical features and outcomes |
|
https://doi.org/10.18632/oncotarget.23200
|
| 35780-35789 |
Reviews
|
| Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion article |
|
https://doi.org/10.18632/oncotarget.26271
|
| 35790-35794 |
Corrections
|
| Correction: Proteomic screening identifies the zonula occludens protein ZO1 as a new partner for ADAM12 in invadopodialike structures |
|
https://doi.org/10.18632/oncotarget.26339
|
| 35795-35795 |
|
| Correction: The path to « the Golden Age » for the treatment of metastatic renal cell carcinoma |
|
https://doi.org/10.18632/oncotarget.26340
|
| 35796-35796 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
